The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

Introduction {#s1}
============

*Perkinsus marinus* and *Perkinsus chesapeaki* cause Dermo disease in oysters and clams in the USA. Described in the early 1950s, Dermo disease is associated with mass mortalities of eastern oysters (*Crassostrea virginica*) in the Gulf Coast [@pone.0111051-Mackin1]; now it is under surveillance by the World Organization for Animal Health (OIE; <http://www.oie.int/>; Aquatic Animal Health Code, Section 11: Diseases of Molluscs). The Chesapeake Bay (Maryland, Virginia, USA) is a clear example of where *P. marinus* has contributed to the decimation of the oyster industry (today\'s production in Maryland is 4.2% of the production in the mid-1960s). The expansion of the *P. marinus* distribution range in the USA has been associated with global warming and the shellfish trade [@pone.0111051-Ford1], [@pone.0111051-Ford2]. Dermo remains an important obstacle to the restoration of oyster populations in numerous eastern states [@pone.0111051-Ford2], [@pone.0111051-Smolowitz1]. Interestingly, *P. marinus* has also been reported with high prevalence in oysters from eastern states with no noticeable mollusk mortality [@pone.0111051-Pecher1], and recent records of *P. marinus* in oysters from the West Coast of North America were not associated with mortalities [@pone.0111051-CceresMartnez1]. The presence of *P. marinus* phenotypes and genotypes might account for differences in virulence [@pone.0111051-Bushek1]--[@pone.0111051-Robledo1]. In the USA, *P. chesapeaki* displays a high preference for infecting clams and it appears to be better adapted to lower salinities and temperatures than *P. marinus* [@pone.0111051-Pecher1] and recently it has been detected in cockles (*Cerastoderma edule*) in Europe [@pone.0111051-Carrasco1]. Worldwide, seven *Perkinsus* spp. have been described, most of them in the last decade with five of them available in *in vitro* culture (reviewed in [@pone.0111051-FernndezRobledo1]).

Compared to parasites of human and veterinary relevance, the pharmacopoeia for marine protozoan parasites is still very limited, and some of these compounds are toxic in the marine environment [@pone.0111051-Leite1], [@pone.0111051-Shridhar1]. *Perkinsus* and other non-photosynthetic relatives of both dinoflagellates and apicomplexans lineages have lost the ability to perform photosynthesis; still, they have retained a cryptic plastid and its pathways (Chromalveolata hypothesis), which are recognized as promising drug targets [@pone.0111051-Keeling1], [@pone.0111051-Fichera1]. Government agencies, drug companies, and non-profit organizations have screened multiple compound libraries against *Plasmodium falciparum* resulting in the Medicines for Malaria Venture (MMV) Malaria Box (<http://www.mmv.org/malariabox>) [@pone.0111051-Spangenberg1]. This compound library is being used to find inhibitors of defined parasite life stages [@pone.0111051-Duffy1], [@pone.0111051-Lucantoni1], to describe mechanisms of action [@pone.0111051-Bowman1], and to find active compounds against other protozoan parasites [@pone.0111051-Bessoff1], [@pone.0111051-Njuguna1]. Here, we followed similar approach and tested the MMV Malaria Box for the discovery of novel hits against *Perkinsus* using an adenosine tri-phosphate (ATP) content-based assay to test *P. marinus* proliferation growth [@pone.0111051-Shridhar1].

Materials and Methods {#s2}
=====================

Materials {#s2a}
---------

The MMV Malaria Box constitutes 200 drug-like and 200 probe-like compounds with activity against the blood-stage of *Plasmodium falciparum* 3D7 (<http://www.mmv.org/research-development/malaria-box-supporting-information>). Stock solutions (20 mM) (Batch April2013; [Table S1](#pone.0111051.s001){ref-type="supplementary-material"}) in dimethyl sulfoxide (DMSO) were diluted in water and tested in the primary screening at a final concentration of 20 µM. The compounds were not repurchased nor re-synthetized; consequently, the results should be considered as primary unconfirmed hits until the identification of these compounds is followed up by a proper confirmation.

Parasite strains and *in vitro* culture {#s2b}
---------------------------------------

Experiments were carried out with eight *P. marinus* strains and five *Perkinsus* species ([Table 1](#pone-0111051-t001){ref-type="table"}). Cultures were maintained in Dulbecco modified Eagle\'s: Ham\'s F12 (1∶2) supplemented with 5% fetal bovine serum in 25 cm^2^ (5 ml) vented flasks in a 26--28°C microbiology incubator as reported elsewhere [@pone.0111051-Gauthier1]. For the compound library screening, *P. marinus* PRA240 [@pone.0111051-Shridhar1], [@pone.0111051-FernndezRobledo2] cultures were expanded in a 75 cm^2^ (30--50 ml) vented flask in a microbiology incubator fitted with orbital shaking (70--80 rpm).

10.1371/journal.pone.0111051.t001

###### *Perkinsus* spp. and *Perkinsus marinus* strains used in the study.

![](pone.0111051.t001){#pone-0111051-t001-1}

  *Perkinsus* sp.[\*](#nt102){ref-type="table-fn"}          Strain         ATCC \#        Location/year of isolation                  Host                                       Reference
  -------------------------------------------------- -------------------- --------- -------------------------------------- --------------------------- -------------------------------------------------------------
  *P. marinus*                                        C13-11 \[MA-2-11\]    50896           Cotuit, MA (USA)/1998            *Crassostrea virginica*   
                                                       LICT-1 \[CT-1\]      50508      Long Island Sound, CT (USA)/1998      *Crassostrea virginica*   
                                                       DBNJ-1 \[NJ-1\]      50509        Delaware Bay, NJ (USA)/1993         *Crassostrea virginica*   
                                                            CB5D4          PRA240        Bennett Point, MD (USA)/2008        *Crassostrea virginica*                 [@pone.0111051-FernndezRobledo2]
                                                            CB5D4          PRA393       GFP mutant derived from PRA240       *Crassostrea virginica*    [@pone.0111051-Shridhar1], [@pone.0111051-FernndezRobledo2]
                                                           HCedar2          50757         Cedar Keys, FL (USA)/1998          *Crassostrea virginica*   
                                                       HTtP14 \[FL-6\]      50763           Fort Pierce, FL (USA)            *Crassostrea virginica*   
                                                             TXsc           50983        Galveston Bay, TX (USA)/1993        *Crassostrea virginica*                     [@pone.0111051-Gauthier2]
  *P. chesapeaki* ( = *andrewsi*)                           A8-4a           50807          Fox Point, MD (USA)/2001             *Macoma balthica*                          [@pone.0111051-Coss1]
  *P. olseni* ( = *atlanticus*)                              ALG1           50984    Ria Formosa, Algarve (Portugal)/2002      *Tapes decussatus*                        [@pone.0111051-Robledo2]
  *P. mediterraneus*                                          G2           PRA238            Menorca (Spain)/2003                *Ostrea edulis*                          [@pone.0111051-Casas2]
  *P. honshuensis*                                        Mie-3G/H8        PRA177    Gokasho Bay, Mie Pref. (Japan)/2002    *Venerupis philippinarum*                     [@pone.0111051-Dungan1]

*Perkinsus marinus* PRA240 was used for the primary screen. A total of eight *P. marinus* strains isolated from oysters from the East and Gulf Coast of the USA and five *Perkinsus* spp. from around the world were used for the secondary screen. In all the cases cultures were maintained in Dulbecco modified Eagle\'s: Ham\'s F12 (1∶2) supplemented with 5% fetal bovine serum.

\**Perkinsus qugwadi* and *Perkinsus beihaiensis* have never been available in culture [@pone.0111051-Blackbourn1], [@pone.0111051-Moss1].

96-Well format *Perkinsus* growth-inhibition primary screen {#s2c}
-----------------------------------------------------------

*Perkinsus marinus* PRA240 (100 µl, 2.0--5.0×10^6^ cells/ml or 2000--4000 relative fluorescence units, RFU) were prepared in sterile 96-well plates (white OptiPlateTM-96, PerkinElmer Life Sciences, Boston, MA). *Perkinsus marinus* cells were exposed once to the MMV Malaria Box (20 µM; final concentration of DMSO was 0.1%; concentrations above 0.1% are toxic to *P. marinus* trophozoites) in triplicate. Control wells (×3) included DMSO with *Perkinsus* cells, culture medium with cells and culture medium with no cells. The effect of the compounds on *P. marinus* proliferation was evaluated using the ATPlite assay at day 4 post-exposure, as reported elsewhere [@pone.0111051-Shridhar1]. Readings for each well were normalized to the control wells with cells and DMSO (100% activity).

Secondary *Perkinsus* growth-inhibition screen (IC~50~) and *Perkinsus* strain and species sensitivity {#s2d}
------------------------------------------------------------------------------------------------------

Six of the best hits from the MMV Malaria Box ([Table 2](#pone-0111051-t002){ref-type="table"}) were retested on *P. marinus* PRA240; the IC~50~ was calculated in an 8-point dose-response curve (10 µM to 0.156 µM) using Prim6 (sigmoidal) (Graphpad Software, Inc.). Eight *P. marinus* strains and five *Perkinsus* spp. ([Table 1](#pone-0111051-t001){ref-type="table"}) were tested to compare their relative sensitivity using 2 µM day 2 post-exposure. *In vitro* cultures *Perkinsus olseni*, *P. chesapeaki*, and *P. mediterraneus* are characterized by either sporulating, making the culture medium acid or remaining in clumps, or having very large trophozoites [@pone.0111051-Robledo2]--[@pone.0111051-Casas1]. Consequently, to standardize the assay, aliquots from the cultures in the exponential phase were used for ATP measurement and then the experimental-well plates seeded with cells- ATP activity equivalent to *P. marinus* PRA240 2.0--5.0×10^6^ cells (2000--4000 RLU) [@pone.0111051-Shridhar1]. The effect of the compounds on *P. marinus* strains and *Perkinsus* spp. proliferation was evaluated as above.

10.1371/journal.pone.0111051.t002

###### List of compounds active against *Plasmodium falciparum* selected for the MMV Malaria Box (<http://www.mmv.org/malariabox>) for secondary *Perkinsus marinus* growth-inhibition screen (IC~50~) and *Perkinsus marinus* strain and *Perkinsus* species sensitivity.

![](pone.0111051.t002){#pone-0111051-t002-2}

  HEOS Compound ID             Target                                  Smiles                          EC~50~ (µM)[\*](#nt103){ref-type="table-fn"}      Set       MW (KDa)   EC~50~ (µM)[\*\*](#nt104){ref-type="table-fn"}
  ------------------ -------------------------- ----------------------------------------------------- ---------------------------------------------- ------------ ---------- ------------------------------------------------
  MMV665941                   Unknown            CN(C)c1ccc(cc1)C(O)(c2ccc(cc2)N(C)C)c3ccc(cc3)N(C)C                      0.255                       Probe-like    389.53                         5.35
  MMV666021                   Yes, 29                   Cc1ccc(cc1)c2cc3C( = O)c4ccccc4c3nn2                              0.094                       Probe-like    272.30                         1.05
  MMV665807             TM protease serine 4           Oc1ccc(Cl)cc1C( = O)Nc2cccc(c2)C(F)(F)F                              ND                        Drug-like     315.67                         2.00
  MMV666102                Functional 17                CN(C)c1ccc(cc1)c2nc3cc(N)ccc3\[nH\]2                                ND                        Drug-like     252.31                         1.77
  MMV396719                Functional 11           n1(c2c(cccc2)n3)c3c4c(cccc4)NC1(C)c5cccc(OC)c5                         1.150                       Drug-like     341.40                         2.08
  MMV006522           Functional 19, Cytotoxic           CCOc1ccc2nc(C)cc(Nc3ccc(Br)cc3)c2c1                              0.480                       Probe-like    357.24                        35.61

\**Plasmodium falciparum* 3D7;

\*\**Perkinsus marinus* PRA240 primary screen.

Results and Discussion {#s3}
======================

MMV Malaria Box screen {#s3a}
----------------------

In this study, we screened the MMV Malaria Box for compounds that might inhibit *P. marinus* proliferation *in vitro*, an approach that has been successfully used to identify compounds against other protozoan parasites [@pone.0111051-Bowman1]--[@pone.0111051-Njuguna1]. In our previous study, the effect of the drugs on *P. marinus* proliferation was evaluated at days 2, 4, and 8 post-exposure; however, it was at day 4 post-exposure when the inhibitory effect(s) of most drugs tested became apparent [@pone.0111051-Shridhar1]. Consequently, for the MMV Malaria Box screening we measured cell viability at day 4 post-exposure. We found that 46% of the compounds active against the *P. falciparum* erythrocyte life stage were also active against *P. marinus* trophozoites ([Table S2](#pone.0111051.s002){ref-type="supplementary-material"}). A total of 58 compounds (31.8%) resulted in at least 50% inhibition; from these compounds, 13 (7.1%) resulted in at least 90% inhibition ([Figure 1](#pone-0111051-g001){ref-type="fig"}). The repertory of available anti- *Perkinsus* drugs has gradually increased over the past two decades thanks to the establishment of the culture methodologies for *Perkinsus* spp. [@pone.0111051-Gauthier2]--[@pone.0111051-Kleinschuster1] ([Figure 2A](#pone-0111051-g002){ref-type="fig"}). Still, prior to this study, the number of available compounds against *Perkinsus* spp. was very limited ([Figure 2B](#pone-0111051-g002){ref-type="fig"}) compared to compounds against protozoan parasites of medical and veterinary relevance [@pone.0111051-Chen1]--[@pone.0111051-Monzote1]. Previous screenings for compounds inhibiting *Perkinsus* proliferation have been based on the strong line of evidence for the presence in *Perkinsus*, like those in apicomplexan parasites, of pathways linked to a relic plastid [@pone.0111051-Leite1], [@pone.0111051-Shridhar1], [@pone.0111051-Stelter1], [@pone.0111051-FernndezRobledo3]. Here we have shown that the MMV Malaria Box offers a promising alternative way of finding compounds effective against *Perkinsus* spp.

![Percentage of inhibition of *Perkinsus marinus* using the MMV Malaria Box.\
Biological triplicate cultures were grown in sterile 96-well plates (100 µl; 2.0×10^6^ cells/ml) and cells were exposed to the MMV Malaria Box (20 µM). The effect of the drugs on *P. marinus* proliferation was evaluated using the ATPlite assay at day 4 post-exposure to the selected drugs. Readings for each concentration were normalized to the control wells with each solvent (100% activity). A total of 122 (67.0%) compounds resulted in at least 50% inhibition; from these compounds, 13 (7.1%) resulted in at least 90% inhibition ([Figure 2](#pone-0111051-g002){ref-type="fig"}).](pone.0111051.g001){#pone-0111051-g001}

![Drug discovery against Dermo disease.\
(A) Time line for the discovery of drugs against Dermo disease, starting when the etiological agent was described until this study. Most of the discoveries did happen after the development of the culture methodologies for *Perkinsus* spp. in 1993 and most studies have been carried out in *in vitro* cultures. (B) Percentage of the compounds active against *Perkinsus* based on their chemical nature. (C) Percentage of available compounds against Dermo tested in *Perkinsus marinus* and *Perkinsus olseni*.](pone.0111051.g002){#pone-0111051-g002}

Secondary *Perkinsus* growth-inhibition screen (IC~50~) {#s3b}
-------------------------------------------------------

Three drug-like and three probe- like of the 13 compounds with the highest inhibitory effect on *P. marinus* ([Table 2](#pone-0111051-t002){ref-type="table"}) were randomly selected for calculating the IC~50~ in an 8-point dose-response curve (10 µM to 0.156 µM). We found that the IC~50~ varied between 1.05 µM for MV66602 and 5.35 µM for MMV665941; for MV006522 the IC~50~ was 35.6 µM a high concentration or leaving the compound longer time would have resulted in a fitted sigmoidal curve. In this study the IC~50~ for the selected compounds ([Figure 3](#pone-0111051-g003){ref-type="fig"}) was in the lower µM range and much lower than for the compounds tested in our previous study [@pone.0111051-Shridhar1], still it was higher than the corresponding *P. falciparum* IC~50~ values ([Table 2](#pone-0111051-t002){ref-type="table"}); consequently, without knowing the mechanism of action of the compounds, we cannot rule out off-target effects due to non-specific cytotoxic agents, including detergent effects, multi-targeting and oxidative effects. The nature of the assays (*Plasmodium falciparum* relies on infected erythrocytes and the *P. marinus* screen is performed in the absence of the host cells) and culture medium can also account for the differences in the IC~50~ values. With a direct life cycle, *P. marinus* trophozoites are phagocytized by the oyster hemocytes [@pone.0111051-Tasumi1], [@pone.0111051-Feng1] where they resist oxidative killing [@pone.0111051-Schott1]. Interestingly, MMV666021 has been involved in the inhibition of glutathione-S-transferase (GST) activity of prostaglandin D2 synthase (PGDS) [@pone.0111051-Hohwy1]. GST are involved in parasite survival by protecting them against oxidative stress from the host or from products derived from their own metabolism [@pone.0111051-Na1], and in *P. falciparum* it has been associated with chloroquine-resistance [@pone.0111051-Rojpibulstit1]. We grow *Perkinsus* in a host cell-free culture medium; hence, if the MMV666021 is indeed affecting the oxidative stress, it is most likely dealing with the ROS derived from the parasites\' own metabolism. *Perkinsus marinus* trophozoites have an expanded transporter repertoire, which is useful not only for transporting nutrients but also for secreting extracellular products (ECP) intended to inactivate the host defense and to break down host tissues [@pone.0111051-Joseph1], [@pone.0111051-Garreis1]. Protease activity variations significantly decrease the migration of hemocytes [@pone.0111051-Garreis1] and have been associated with differences in the average cell size and growth rate [@pone.0111051-Brown1]. MMV665807 is believed to target transmembrane serine proteases. Interestingly, the *P. marinus* genome encodes multiple putative serine protease genes (*e.g.* XM_002788359, XM_002786609, XM_002766692); numerous studies have identified serine protease activities in the spent medium of cultured *P. marinus* and *P. mediterraneus* [@pone.0111051-Faisal1], [@pone.0111051-Casas2] and mutations in the promoter region of serine protease inhibitors (SPIs) in *C. virginica* which confer resistance to Dermo disease [@pone.0111051-He1], [@pone.0111051-Yu1]. The parasite proteases could be the target of MMV665807; however, to prove this hypothesis would require further experiments outside the scope of this study.

![Secondary *Perkinsus marinus* growth-inhibition screen (IC~50~).\
Biological triplicate cultures were exposed to an 8 -point dose-response curve (10 µM to 0.156 µM). The effect of the drugs on *P. marinus* proliferation was evaluated as above.](pone.0111051.g003){#pone-0111051-g003}

*Perkinsus marinus* strains and Perkinsus species sensitivity {#s3c}
-------------------------------------------------------------

Our results comparing the effect of a single compound concentration (2 µM) against seven *P. marinus* strains indicate that for MMV666021, MMV665807 and MMV666102, the inhibition of the different strains was within an equivalent range ([Table 3](#pone-0111051-t003){ref-type="table"}). Interestingly, for MMV665941, MMV396719 and MMV006522, there was a high degree of variability among the *P. marinus* strains. The presence of *Perkinsus* in low salinity estuaries and the sudden spread of the parasite between oyster beds is often seen as indicating the presence of strains adapted to low salinity and strains of variable virulence; parasites isolated from the Atlantic coast are more virulent than Gulf isolates [@pone.0111051-Perkins1], [@pone.0111051-Bushek2]. Indeed, *P. marinus* "races" and genetic strains have been documented along the Atlantic and Gulf coasts of the USA [@pone.0111051-Bushek1]--[@pone.0111051-Robledo1]. *Perkinsus marinus* strains from Maryland and Virginia appeared to be more susceptible to treatment with the antimalarial drug Quinine (130 µM) [@pone.0111051-Panko1]. We also found strain variability to the compounds tested; *P. marinus* HCedar 2 from Florida appears to be much more sensitive to MMV006522 than the other *P. marinus* strains. On the other hand, MMV665941 appears to be less effective against *P. marinus* LICT-1 \[CT-1\] and DBNJ-1 \[NJ-1\], isolated from oysters from Connecticut and Delaware respectively. *Perkinsus marinus* LICT-1 \[CT-1\] also appears to be the strain less sensitive to MMV396719. There is a genetic base beneath *P. marinus* strains [@pone.0111051-Reece1], [@pone.0111051-Robledo1] and recent microsatellite analyses suggest that *P. marinus* utilizes both sexual and asexual reproduction and, over the short-term, selection acts upon independent parasite lineages rather than upon individual *loci* in a cohesive, interbreeding population [@pone.0111051-Thompson1]. Drawing a parallel to other protozoan parasites with markedly clonal population structure and variable degree of virulence [@pone.0111051-Sibley1], it is possible that the observed variability respond to a clonal population structure (strains derived from one original single clone) with variable virulence. Indeed, Reece et al. [@pone.0111051-Reece1] grouped 76 *P. marinus* isolates in 12 different composite genotypes with \>88% of isolates possessing one of three predominant genotypes.

10.1371/journal.pone.0111051.t003

###### Activity of antimalarial drug-like and probe-like (2 µM) compounds on *P. marinus* strains and *Perkinsus* spp. determined at day 2 post-exposure.

![](pone.0111051.t003){#pone-0111051-t003-3}

                                                             HEOS Compound ID                                                                        
  -------------------- -------------------- --------------- ------------------ ------ ------ ----- ------ ----- ------ ------ ------- ------ ------- ------
  *P. marinus*          C13-11 \[MA-2-11\]   Massachusetts         34.9         1.9    86.3   1.5   97.1   0.8   74.5   1.6    39.7    7.7    −10.3   0.2
                         LICT-1 \[CT-1\]      Connecticut         −20.7         10.2   79.6   1.6   95.6   0.2   64.6   1.9    36.7    10.2   −4.6    7.7
                         DBNJ-1 \[NJ-1\]       Delaware            −6.8         11.0   71.6   3.2   92.4   1.1   72.6   1.7    −1.3    8.6    −47.4   3.3
                              CB5D4            Maryland            34.3         2.3    84.8   2.4   96.4   0.7   64.4   1.7    44.4    3.6     4.5    2.9
                            CB5D4-GFP          Maryland            41.8         3.0    85.8   1.7   95.2   1.6   64.7   3.7    48.1    2.8    −14.3   6.9
                             HCedar2            Florida            39.7         5.6    86.5   1.8   97.5   0.1   75.0   0.3    54.4    7.6    20.9    3.0
                         HTtP14 \[FL-6\]        Florida            44.0         3.1    82.3   5.1   95.0   0.9   59.1   4.1    53.9    2.2    −1.7    5.0
                               TXsc              Texas             10.7         6.8    72.5   3.8   91.5   0.6   68.1   2.3     7.9    10.5   −22.4   8.3
  *P. chesapeaki*             A8-4a            Maryland           −47.8         15.6   55.7   6.8   84.1   2.0   88.0   3.3    −12.0   8.2    −96.0   9.0
  *P. olseni*                  ALG1            Portugal            14.3         14.7   80.4   1.4   94.9   0.7   51.1   1.3    22.5    1.4    10.5    3.2
  *P. mediterraneus*            G2               Spain            −41.9         27.4   78.2   1.3   92.6   0.4   57.0   7.5    36.5    10.9    1.2    21.7
  *P. honshuensis*          Mie-3G/H8            Japan            −38.5         15.4   86.2   3.3   95.4   1.5   8.8    14.1   64.6    4.5    38.0    5.9

Data expressed as inhibition mean (%).

We also compared all five *Perkinsus* spp. in culture using the panel of six drug-like and probe-like compounds at a concentration within the range of the determined IC~50~ (2 µM). We found that MMV666021, MMV665807 and MMV666102 were active against all five *Perkinsus* spp. Interestingly, some compounds were not equally effective against all the *Perkinsus* spp. *P. chesapeaki* was not sensitive to MMV665941, MMV396719 and MMV006522 at the concentration tested. *Perkinsus chesapeaki* affects both oysters and clams along the East Coast of the USA [@pone.0111051-Pecher1] and recently it was detected in cockles from Europe [@pone.0111051-Carrasco1]. Compared to other *Perkinsus* spp., *P. chesapeaki* A8-4a is characterized by making the culture medium acidic [@pone.0111051-Coss1], [@pone.0111051-Coss2], which could affect the potency or the uptake of the compounds tested. Both *P. mediterraneus* G2 and *P. honshuensis* Mie-3G/H8 were not sensitive to MMV665941 at the concentration tested; interestingly, they were also less sensitive to MMV666102, a compound that showed a high degree of inhibition in most *P. marinus* strains and in *P. chesapeaki*. This study highlights an unexpected degree of variability between *Perkinsus* spp. A plausible explanation could be variations in the propagation rates and strategies in the *in vitro* culture affecting the uptake of the compounds. For example, some *Perkinsus* spp. in culture appear to be "locked" at the trophozoite stage while other *Perkinsus* spp. continuously zoosporulate [@pone.0111051-Coss2], [@pone.0111051-Casas3]. *P. mediterraneus* cell density only increases two- to sixfold over a 6-week period compared to ten- to thirtyfold in *P. marinus* [@pone.0111051-Casas2]. With the culture medium indicated above, both *P. mediterraneus* G2 and *P. honshuensis* Mie-3G/H8 are characterized by forming large in clumps in culture; whether this phenotype conditions the uptake of the compounds remains to be demonstrated. To answer these questions would require fine-tuning cultures and dedicated experiments outside the scope of this preliminary large screening.

Conclusions {#s4}
===========

By taking full advantage of both the open access Malaria Box and having *Perkinsus* spp. in culture, we have identified numerous compounds that affect the *in vitro* proliferation of the parasite. These primary "hits", if confirmed, would expand the number of available compounds against *P. marinus* fivefold. To determine whether the drugs tested in this study will be effective in treating or preventing *P. marinus* infections in bivalves, we must first find a delivery method that administers an effective dose to the oyster tissue and toxicity to the bivalve hosts and other organisms in the environment [@pone.0111051-Shridhar1]. In this study, we have taken an indirect approach for identifying and characterizing geographic phenotypes on the basis of resistance to selected compounds from the Malaria Box. At this point, we do not have an explanation for this variability. Most of the compounds tested have a very low molecular weight and are most likely taken up non-specifically by the parasite transporters \[*P. marinus* genome encodes excess in secondary active transporters (41 out of 66 super families) including Major Facilitator Superfamily, Amino Acid/Auxin Permease, and Drug/Metabolite, unpublished data\]. This would require more targeted research outside of the scope of this work. Moreover, these findings should also make the scientific community aware that the conclusions may be limited or can change depending on the particular strain used in the study. What the targets are, and the biological functions affected by these compounds in *Perkinsus* spp., remains an open question. Still, *Perkinsus* can be use as a model to ascertain the mechanism of action of the probe-like compounds.

Supporting Information {#s5}
======================

###### 

**List of Medicines for Malaria Venture Malaria Box compounds developed against** ***Plasmodium falciparum*** **3D7 and used in this study (** <http://www.mmv.org/research-development/malaria-box-supporting-information> **).**

(XLSX)

###### 

Click here for additional data file.

###### 

**Percentage of inhibition of** ***Perkinsus marinus*** **trophozoites growth using drug-like compounds and probe-like compounds (20 µM) at day 4 post-exposure.**

(XLSX)

###### 

Click here for additional data file.
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